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ABSTRACT
T-cell receptor (TCR)-engineered T cells are a novel
option for adoptive cell therapy used for the treatment of
several advanced forms of cancer. Work using TCR-
engineered T cells began more than two decades ago,
with numerous preclinical studies showing that such
cells could mediate tumor lysis and eradication. The
success of these trials provided the foundation for clini-
cal trials, including recent clinical successes using TCR-
engineered T cells to target New York esophageal squa-
mous cell carcinoma (NY-ESO-1). These successes
demonstrate the potential of this approach to treat can-
cer. In this review, we provide a perspective on the cur-
rent and future applications of TCR-engineered T cells for
the treatment of cancer. Our summary focuses on TCR
activation and both pre-clinical and clinical applications
of TCR-engineered T cells. We also discuss how to
enhance the function of TCR-engineered T cells and
prolong their longevity in the tumor microenvironment.
KEYWORDS T-cell receptor, tumor antigen, TCR-
engineered T cells, neoantigen, tumor microenvironment
INTRODUCTION
It was shown as early as 1976 that interleukin-2 (IL-2),
regarded as a T-cell growth factor, induced T-cell prolifera-
tion without loss of effector function in vitro (Morgan et al.,
1976). It is now known that the cytokine IL-2 is crucial for
sustained clonal expansion of responding T cells. A study by
Rosenberg et al. demonstrated that syngeneic tumor-inﬁl-
trating lymphocytes (TILs) could undergo expansion in the
presence of IL-2. Adoptive transfer of these TILs to murine
models was shown to lead to regression in lung and liver
tumors (Rosenberg et al., 1986). Subsequently, adoptive cell
therapy using autologous TILs has become one of the most
effective approaches to induce long-lasting regression in
patients with metastatic melanoma (Rosenberg et al., 1988;
Dudley et al., 2002; Scanlan et al., 2002; Rosenberg et al.,
2011; Pilon-Thomas et al., 2012; Radvanyi et al., 2012;
Besser et al., 2013). The presence of TILs has also been
associated with improved prognosis in other cancer types,
including ovarian, colon, and breast cancer (Clemente et al.,
1996; Sato et al., 2005; Galon et al., 2006; Loi, 2013).
Early studies found that TILs isolated from melanoma
patients recognized two non-mutated melanoma melanocyte
differentiation proteins: MART-1 and gp100 (Kawakami
et al., 1994a; Kawakami et al., 1994b). MART-1 and gp100
proteins are often expressed by melanocytes in the skin,
eye, and ear. However, many patients who present complete
cancer regression did not have a toxic response after treat-
ment with TILs targeting MART-1 or gp100. This demon-
strated that it is the antigen-speciﬁc T cells in TILs that are
crucial for cancer regression. There are however several
hurdles to purifying the amount of antigen-speciﬁc T cells
necessary to be used as a therapy: (1) it is difﬁcult to isolate
tumor-speciﬁc T cells from many cancer patients; (2) it takes
considerable time to obtain a therapeutic amount of tumor-
speciﬁc Tcells. With the introduction of T-cell receptor (TCR)
engineering technologies, it became possible to produce
antigen-speciﬁc T cells. Treatment with engineering, tumor
antigen-speciﬁc T cells has demonstrated signiﬁcant clinical
successes in patients with metastatic melanoma, colorectal
carcinoma, synovial sarcoma, and multiple myeloma (Mor-
gan et al., 2006; Johnson et al., 2009; Parkhurst et al., 2011;
Robbins et al., 2011; Rapoport et al., 2015; Robbins et al.,
2015) (Fig. 1). Tumor antigen-speciﬁc TCR gene-engineered
T cells are therefore considered as a potentially “off-the-
shelf” treatment for cancer patients.











THE FOUNDATION OF TCR ACTIVATION
TCR recognition of pMHC molecules
TCR is expressed on the surface of T cells and consists of two
distinct protein chains. In the majority of mature T cells, the
TCR consists of α and β chains, although there is a smaller
population of T cells in which the TCR consists of γ and δ
chains. Antigen recognition by the αβTCR is central to the
function of the adaptive immune system. αβTCR bind to the
peptide major histocompatibility complex (pMHC) on the sur-
face of antigen-presenting cells. The interaction between an
αβTCR and a pMHC is highly speciﬁc owing to the fact that T
cells are able to distinguish between rare foreign pMHCs and
the abundant self pMHC molecules (Germain and Stefanova,
1999). CD8+ T cells play an important role in the adaptive
immune response in cancer patients and are activated by TCR
recognition of speciﬁc peptide epitopes. These peptide epi-
topes are largely generated from endogenous proteins that are
presented by MHC class I proteins on the surface of tumor cells
(Phan and Rosenberg, 2013). MHC class I proteins are
membrane proteins that are expressed on almost all nucleated
cells. They are encoded by several families of human leuko-
cyte antigen (HLA-A, B, and C) genes (Brown et al., 2014).
Expression of HLA genes can be upregulated by interferon
(IFN) signaling, but the expression is often notably down-reg-
ulated in tumors. The degree of down-regulation correlates with
immune evasion and disease progression in patients with
cancer (Agrawal and Kishore, 2000; Leone et al., 2013). T cell
activation requires translation of pMHC antigen binding to the
TCR and then on to intracellular signaling pathways (Zhang
and Bevan, 2011; Obst, 2015; Pageon et al., 2016). Ex vivo
and in vivo studies demonstrate that the dose of antigen pre-
sented determines the nature of cytokine expression in T cells
(Corse et al., 2011; Tkach et al., 2014).
TCR signaling transduction
Naïve T cells undergo clonal expansion of between 10 and
20 rounds of cell division after activation by TCR/pMHC
interaction (Zhang and Bevan, 2011; Obst, 2015). Compared
with naïve T cells, antigen-stimulated T cells substantially
increase antigen responsiveness via a process termed
“functional avidity maturation” (Margulies, 2001; Slifka and
Whitton, 2001). Studies have found that antigen-stimulated T
cells exhibit greater proliferation and cytokine production
than naïve T cells (Akbar et al., 1988; Byrne et al., 1988;
Sanders et al., 1989; Sallusto et al., 1999). T cells recognize
antigen-MHC complexes through the TCR-CD3 cluster. After
interaction between the MHC and TCR, several classes of
protein are then recruited to the plasma membrane by acti-
vated receptors to participate in signal propagation (Fig. 2).
Phospholipase C-γ1 (PLC-γ1) cleaves molecules of mem-
brane phospholipid phosphatidylinositol bisphosphate
(PIP2), into inositol triphosphate (IP3), and diacylglycerol
Leukapheresis





Clone TCR α and












Figure 1. Process of TCR-engineered T cells therapy. T cells are isolated from patient blood or tumor tissue. TCR α and β chains
are then isolated from single T-cell clones and inserted into a lentivirus or retrovirus vector. Tcells isolated from the peripheral blood of
the patient can be modiﬁed with the lentivirus or retrovirus vector to encode the desired TCRαβ sequences. These modiﬁed Tcells are
then expanded in vitro to obtain sufﬁcient numbers for treatment and re-infusion back into the patient.
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(DAG). The interaction of IP3 with its receptors in the
endoplasmic reticulum upregulates the level of Ca2+ in the
cytosol, activating the Ca2+-binding protein calmodulin. This
subsequently regulates nuclear factor of activated T cells
(NFAT) proteins. Additionally, DAG activates the Ras/extra-
cellular regulating kinase (Erk) pathway, modulating the
nuclear factor Fos. Through all of these interacting signaling
pathways, T cells are activated, releasing numerous cytoki-
nes and chemokines, including IFN-γ, Granzyme B, and IL-2
(Abraham and Weiss, 2004; Smith-Garvin et al., 2009).
The function of T lymphocytes is largely regulated by TCR
signaling. Studies have shown that initial TCR signaling via
p38 leads to successive induction of Vitamin D receptor
(VDR) and PLC-γ1, both of which are required for classical
TCR signaling and T cell activation (von Essen et al., 2010).
Genetically blocking TCR internalization inhibits T cell
expansion, demonstrating that TCR signaling is required for
T cell proliferation. TCR internalization was also required for
sustained signaling and activation of key metabolic
pathways, including the mechanistic target of rapamycin
(mTOR) (Willinger et al., 2015). Acting to control T cell acti-
vation, T cell anergy is a tolerance mechanism in which
lymphocytes are intrinsically functionally-inactivated follow-
ing antigen encounter. This phenomenon is often observed
in the tumor microenvironment. Zheng et al. found that early
growth response protein 2 (Egr2) was necessary for in vivo
anergy induction when using antigen-induced and tumor-in-
duced anergy models. Egr2 is therefore considered an
essential transcriptional regulator of T cell anergy (Zheng
et al., 2012). The activation status of T cells and the level of
immune response are further controlled by various co-stim-
ulatory (CD28, inducible T cell co-stimulator (ICOS), and
OX40) and co-inhibitory (cytotoxic T lymphocyte-associated
antigen-4 (CTLA-4), programmed death 1 (PD-1)) molecules
(Keir et al., 2008; Chen and Flies, 2013). For example, in the
absence of the immune checkpoint protein PD-1, the fusion
antibody B7H1-Ig can augment T cell proliferation and








































Figure 2. Schematic demonstration of TCR signaling. T cells recognize pMHC complexes through the TCR-CD3 cluster. Several
classes of proteins are then recruited to the plasma membrane by the activated receptors and participate in signal propagation.
Phospholipase C-γ1 (PLC-γ1) cleaves molecules of the membrane phospholipid phosphatidylinositol bisphosphate (PIP2) into
inositol triphosphate (IP3) and diacylglycerol (DAG). The interaction of IP3 with its receptors in the endoplasmic reticulum up-
regulates the level of Ca2+ in the cytosol, further activating the Ca2+-binding protein calmodulin. NFAT, as a nuclear factor of activated
T cells, is regulated by the calcium pathway. DAG is primarily involved in the activation of the Ras/Erk pathway. T cells are activated
though these signaling pathways, releasing IFN-γ, Granzyme B, IL-2, and so on.
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intervene and augment or down-regulate immune response
based on B7H1-mediated pathways (Deng et al., 2014).
APPLICATION OF TCR-ENGINEERED T
LYMPHOCYTES
A great deal of scientiﬁc studies have shown that TCR-
engineered Tcells can target and kill cancer cells expressing
appropriate antigens (Parkhurst et al., 2011; Cohen et al.,
2015; Kageyama et al., 2015; Rapoport et al., 2015; Stronen
et al., 2016). However, for treatment to be feasible, it is
necessary to ﬁrst enrich TCR-gene modiﬁed antigen speciﬁc
T cells in vitro. Adoptive cell therapy with these engineered
cells would be a precise therapy as it targets antigens
expressed on cancer cells present in the patient. We will
next examine the application of this therapy for the treatment
of cancer.
Selection of an appropriate antigen
Cancer cells can express proteins during development that
are different from those found in untransformed cells. Certain
antigens that are more frequently expressed by similar
tumors are appealing candidates for therapies utilizing
immune recognition. These antigens can be unique or
shared. Shared antigens are divided into tumor differentia-
tion antigens, over-expressed antigens, and shared tumor-
speciﬁc antigens (http://cancerimmunity.org/peptide/). Many
shared tumor-speciﬁc antigens, encoded by cancer-germline
genes, have been identiﬁed. These antigens can induce an
immune responses and are promising candidate targets for
use in vaccination or T cell therapy, such as melanoma-as-
sociated antigen (MAGE)-A3 (Zhang et al., 2003), MAGE-A4
(Zhang et al., 2002), and New York esophageal squamous
cell carcinoma (NY-ESO)-1 (van der Bruggen et al., 1994;
Valmori et al., 2000; Van Der Bruggen et al., 2002). Many
studies have also reported that tumor differentiation antigens
and overexpressed antigens can evoke T cell responses,
including MART-1, gp100, carcino-embryonicantigen (CEA),
and p53 (Kawakami et al., 1995; Kawashima et al., 1998;
Barfoed et al., 2000). In addition to shared antigens, unique
antigens also have potential to be used as a targeted
treatment. Unique antigens are abnormal proteins that are
only expressed by tumor cells. Viral associated antigens
found in some cancers can be used to produce antigen-
speciﬁc T cells, human papilloma virus for example (Draper
et al., 2015).
In the past 3 years, neoantigen has garnered much
attention as a potential precision immunotherapy. Neoanti-
gens are generated from somatic point mutations in tumor
tissues that are absent in normal tissue. Whole genome or
exome sequencing can be applied to identify optimal
neoantigen candidates for personalized cancer treatment.
RNA sequencing can be performed to examine expression
and predict whether a neoepitope will be presented by the
MHC to be recognized by T cells (Robbins et al., 2013; van
Rooij et al., 2013; Brown et al., 2014). In 2016, a study found
that mutation-reactive T cells could be enriched from donor-
derived T cells and used as an effective therapy for the
treatment of patients with metastatic cancer (Prickett et al.,
2016; Stronen et al., 2016). CD4+ and CD8+ T lymphocytes
have been shown to target epitopes arising from epigenetic,
transcriptional, translational, and post-translational alter-
ations of tumor cells (Coulie et al., 2014). More recently,
technological breakthroughs have shown that numerous
endogenous mutant cancer proteins are unique to tumor
cells. These can be processed into peptides and presented
on the surface of tumor cells leading to these cells being
recognized in vivo as “non-self” or foreign by the immune
system. Targeting highly speciﬁc neoantigens would enable
immune cells to distinguish cancer cells from normal cells
and avoid the risk of autoimmunity (Bobisse et al., 2016).
Neoantigens therefore represent ideal targets for successful
immunotherapy.
Recent exciting results have demonstrated that TILs
responding to patient neoantigens can be detected at much
higher frequencies than other types (Robbins et al., 2013;
van Rooij et al., 2013; Linnemann et al., 2015). Several
studies have also found that monoclonal antibodies directed
against CTLA-4 are particularly effective at treating cancers
with a high burden of somatic mutation (Snyder et al., 2014;
Van Allen et al., 2015). In lung and bladder cancer patients
treated with pembrolizumab, an antibody targeting PD-1, the
non-synonymous mutation burden strongly associates with
clinical efﬁcacy (Powles et al., 2014; Rizvi et al., 2015).
Isolation and reinfusion of neoantigen-speciﬁc Tcells may be
required to mediate tumor regression without inducing on-
target but off-tumor toxicities (Klebanoff et al., 2016). The
best currently available technology to obtain large amounts
of neoantigen speciﬁc T cells is to insert TCR sequences
targeting identiﬁed neoantigens into T cells in vitro. For
example, transgenic CD4+ lymphocytes that recognize a
mutant tumor-speciﬁc neoantigen ERBB2 protein induced
sustained tumor regression in a patient with cholangiocar-
cinoma (Tran et al., 2014). These ﬁndings indicated that it
may be feasible to develop treatments based on the adoptive
transfer of TCR-engineered T cells sorted with tetramers
bearing mutated epitopes that recognize autologous
peripheral T cells (Cohen et al., 2015; Gros et al., 2016).
Further interesting results revealed that CD8+PD-1+ cell
populations from PBMCs and TILs had lymphocytes target-
ing patient speciﬁc neoantigens (Gros et al., 2016; Pasetto
et al., 2016). However, another study found that the lack of a
deﬁned neoantigen resulted in tumor cell resistance in a
transplantable tumor model (Matsushita et al., 2012). Whe-
ther the neoantigen repertoire in human tumors is stable and
therefore consistently targetable is currently unclear.
Verdegaal et al. designed a study to observe the landscape
of neoantigen dynamics and reveal any detectable stability.
Their data demonstrated that speciﬁc T cell-recognized
neoantigens could be lost by either reduced transcript
expression or complete loss of the mutant allele (Verdegaal
REVIEW Yu Ping et al.









et al., 2016). Cancer immunotherapy with neoantigen
speciﬁc T cells should therefore aim to exploit the adaptive
capacity of the immune system. Based on these promising
results, it may be possible that, in the near future, neoantigen
speciﬁc T cells could be used as a novel strategy to develop
personalized therapies to treat cancer.
Candidate target antigens that are used for TCR-
engineered T cell treatment require three features if they
are to be utilized: (1) they must be selectively expressed
in tumors and not in normal tissues (tumor speciﬁcity);
(2) they are related to oncogenesis (tumor addiction); (3)
they are able to evoke a T-cell response (immuno-
genicity) (Debets et al., 2016). Broadly speaking,
choosing an appropriate antigen is the ﬁrst and most
important step to determine the effectiveness of TCR-
engineered T cells.
Identiﬁcation of TCR sequences
Identifying TCR sequences is inherently difﬁcult because
each T cell contains its own unique TCR that recognizes a
distinct set of pMHC molecules. Several methods have been
developed to identify TCR sequences from single T cells
(Fig. 3). Culturing of T cell clones is the canonical method to
identify TCR sequence. Brieﬂy, CD8+ or CD4+ T cells are
puriﬁed from peripheral blood mononuclear cells (PBMCs).
Serial dilutions allow single T cells being seeded into
individual wells of 96-well plates. Finally, these single cells
are propagated, generating T-cell clones. The TCR α chain
and β chain from these T cell clones are identiﬁed and
sequenced (Nishimura et al., 1994; Zhang et al., 2010).
Using this method, several antigen-speciﬁc T cells have
been identiﬁed that effectively recognize relevant antigens,
including tumor antigens. The efﬁcacies of these tumor-
speciﬁc TCRs to treat cancer have been tested in clinical
trials using engineered TCRs (Morgan et al., 2006; Robbins
et al., 2015). NY-ESO-1 speciﬁc TCR-T cells are the most
thoroughly examined and their therapeutic potential has
been tested in synovial cell sarcoma, melanoma, and mye-
loma (Robbins et al., 2011; Rapoport et al., 2015; Robbins
et al., 2015).
Recently, single cell RT-PCR and pairSEQ methods have
been developed to more rapidly identify TCR sequences.
Single cell RT-PCR allows the transcriptomes of thousands
of cells to be processed simultaneously (Wu et al., 2014;
Redmond et al., 2016). This method can identify the unique
TCR and the paired α and β heterodimer of each T cell and
has been successfully used to identify paired α and β chains
from 91 naïve CD4+ T helper cells in mice (Mahata et al.,
2014). PairSEQ technology can leverage the diversity of
TCR sequences to accurately identify many TCR α and β
chain sequences in a single high throughput experiment.
Howie et al. used this technology to pair hundreds of thou-
sands of TCR α and β chain sequences from PBMCs
Single T cell + feeder cells + cytokines
Single T cell in 96-well plate
T cells 











Figure 3. Three typical procedures to obtain TCR sequence. Antigen responsive T cells are isolated, speciﬁc TCR genes are
identiﬁed by single clone derived-cDNA sequencing (I), single cell sequencing (II) or paired sequencing of bulk DNA (III).
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isolated from two healthy donors, as well as thousands of
sequences from TILs in nine pairs of matched tumor and
blood samples (Howie et al., 2015). Pasetto et al. applied
PairSEQ technology to identify TCR sequences of T cells
derived from 12 fresh metastatic melanomas TIL. This study
successfully identiﬁed several sequences that showed
reactivity against tumor antigens (Pasetto et al., 2016). In
summary, PairSEQ is an exciting high throughout technology
that can be used to identify the TCR sequences of TILs. This
information can then be used to engineer Tcells that express
antigen speciﬁc TCRs. These new technologies have great
potential to boost development of TCR-engineered T cell
therapy.
Preclinical studies
Following the identiﬁcation of tumor antigen-targeting TCRs
and their introduction into T cells, it is necessary to perform
functional assessment to analyze the sensitivity of T cell
responses towards the cognate peptides or autologous tumor
cells (Dembic et al., 1986; Kessels et al., 2001). Targeting
shared tissue differentiation antigens, such as MART-1,
gp100 and CEA, will likely come with the price of toxicity to
normal cells in critical organs. It is therefore also necessary to
evaluate off-tumor toxicities of TCR-engineered T cells.
Although some antigens are not widely expressed, such as
the cancer-testis NY-ESO-1 and MAGE families that are
expressed on tumor tissue, fetal tissue, and adult testes but
not on other normal adult tissues, the safety and afﬁnity of
these TCR-engineered T cells should still be assessed. Par-
khurst et al. developed a mouse model to isolate CEA-reac-
tive TCRs from splenocytes and perform functional
assessment. In this study, they proved that the modiﬁed CEA-
reactive TCRs were good candidates for future gene therapy
and also showed the power of selected amino acid substitu-
tions in the antigen-binding regions of TCR to enhance TCR
reactive afﬁnity (Parkhurst et al., 2009). Kunert et al. isolated
10 TCR sequences against four MAGE-C2 epitopes from
melanoma patients and designed a set of experiments to
evaluate TCR-transgenic T cell function (Kunert et al., 2016).
Two MAGE-A3 speciﬁc TCRs were isolated from PBMCs of
two melanoma patients after MAGE-A3 vaccination. These
TCRs recognized MAGE-A3 peptides presented by HLA-
DPB1*04:01. The speciﬁcity and afﬁnity of these two TCRs
were compared and it was found that 6F9 TCR speciﬁcally
recognizedMAGE-A3, but not other members of the MAGE-A
family in the context of HLA-DPB1*04:01. The 6F9 TCR was
selected for potential TCR gene therapy targeting MHC class
II-restricted MAGE-A3 (Yao et al., 2016). An additional issue
is that manymodiﬁed Tcells circulating in patients do not have
any therapeutic effect because they possess decreased
retroviral transgene expression (Kohn et al., 1998). Some
studies have reported possible methods to improve TCR
gene transfer and to provide a stable system for
immunotherapy. Fujio et al. used two independent
monocistronic retrovirus vectors to generate ovalbumin
(OVA)-speciﬁc TCR-Tcells. These cells showed a remarkable
response to antigen (Fujio et al., 2000). Additionally, a len-
tiviral vector carrying a bidirectional promoter was used in the
Bobisse et al. study. This gene delivery system demonstrated
increased transfer efﬁciency, suggesting lentiviral vectors
may be a valid tool for TCR expression in immunotherapy
(Bobisse et al., 2009). These preclinical experiments can help
guide the application of TCR-T cells in clinical trials but it is
essential that new TCRs targeting tumor antigens are tested
for their afﬁnity, toxicity, and safety.
Clinical trials
Adoptive immunotherapy using TCR-engineered T cells has
become an important strategy for cancer therapy (Rosenberg
and Restifo, 2015) and recent clinical trials have provided
encouraging results (Table 1). It was ﬁrst reported that MART-
1 TCRmodiﬁed lymphocytes could mediate tumor regression
in humans in 2006 (Morgan et al., 2006). Clinical trials of
MART-1 TCR-engineered T cells in 2009 and 2014 also
demonstrated this phenomenon (Johnson et al., 2009; Cho-
don et al., 2014). Johnson et al. showed that 19% patients
treated with gp100 TCR-engineered T cells experience an
objective antitumor response (Johnson et al., 2009). In addi-
tion to differentiation antigens, clinical trials have also exam-
ined cancer-testis antigens, such as MAGE-A3 and NY-ESO-
1. In clinical trials using a TCR targeting HLA-A*0201-re-
stricted NY-ESO-1 antigen, objective responses were
observed in more than 50% of patients with synovial cell
sarcoma, melanoma, and myeloma (Robbins et al., 2011;
Rapoport et al., 2015; Robbins et al., 2015). Kageyama et al.
conducted a clinical trial examining TCR-modiﬁed Tcells with
a HLA-A*2402-restricted MAGE-A4 in the treatment of eso-
phageal cancer. These TCR-modiﬁed T cells could be
detected in vivo for a prolonged period of time and three
patients present minimal tumor lesions for more than 27
months (Kageyama et al., 2015). These clinical trials
demonstrate that there can be dramatic tumor regression
using TCR-engineered T cells therapy. This has elicited con-
siderable enthusiasm, although it must be noted that most of
these clinical trials used only a small number of cancer
patients. Additionally, although there has been great progress
in adoptive cell therapy with TCR-engineered T cells, some
unexpected toxicities have occurred. In a clinic trial using
TCR-engineered Tcells targetingmetastatic colorectal cancer
and a high avidity CEA-reactive TCR, all three patients
developed severe transient inﬂammatory colitis due to the
TCR reacting to CEA-expressing normal colon epithelium
cells (Although one patient had an objective regression of
cancermetastatic to the lung and liver) (Parkhurst et al., 2011).
In another study, two patients died of cardiogenic shock after
infusionwith Tcells engineeredwith a TCRagainst HLA-A*01-
restricted MAGE-A3. The artiﬁcially modiﬁed MAGE-A3 TCR
had 4 substitutions in the alpha chain of the CDR2 region and
REVIEW Yu Ping et al.









retained the wild type sequences in the beta chain to increase
the TCR afﬁnity. This afﬁnity-enhanced TCR may have rec-
ognized an epitope derived from an unrelated protein
expressed by normal cardiac tissue, but the parental MAGE-
A3-speciﬁc TCR may also have expanded in the patient
without cardiac toxicity through natural thymic selection pro-
cesses (Linette et al., 2013). A further study also resulted in
two patients lapsing into comas and subsequently dying after
treatment with autologousMAGE-A3 TCRengineered-Tcells.
In this study, the modiﬁed T cells also recognized an MAGE-
A12-derived epitope that was detected in human brain (Mor-
gan et al., 2013). Potential cross-reactivity makes it essential
to carefully evaluate the afﬁnity of TCRs and select the
appropriate antigens for safe clinical application of TCR-
engineered Tcells.
IMPROVING THE FUNCTION OF TCR-ENGINEERED
T CELLS IN TUMOR MICROENVIRONMENT
Improving the function of TCR-engineered T cells is crit-
ical to overcome inhibitory factors within the tumor
microenvironment and elicit tumor regression. Many
efforts to enhance antigen reactivity and circumvent T cell
tolerance have focused on increasing TCR signal
strength and generating highly functional T cells. Immune
checkpoint proteins, such as PD-1 and CTLA-4, can
prevent the activation of T cells in immune system.
Blocking the PD-1 pathway has been shown to improve
the function of TILs and enhance antitumor immunity
(Herbst et al., 2014; Tumeh et al., 2014). It is therefore
likely that the PD-1/PD-L1 signaling pathway is a major
negative feedback regulator of antigen responsiveness
(Okazaki et al., 2013; Honda et al., 2014). Other evidence
has implicated PD-1 signaling in modulating the phos-
phoinositide3-kinase (PI3K), AKT and RAS pathways and
cell cycle control (Parry et al., 2005; Patsoukis et al.,
2012a; Patsoukis et al., 2012b). TCR-engineered T cells
expressing a high level of the inhibitory receptor PD-1
reduced their functional activity (Perez et al., 2015). The
efﬁcacy of NY-ESO-1 TCR-engineered T cells was aug-
mented when used in combination with anti-PD-1 anti-
body (Moon et al., 2016). In addition, cancer cells can
inﬂuence the local microenvironment by releasing extra-
cellular signals, promoting tumor angiogenesis, and
inducing peripheral immune tolerance. Conversely,
immune cells in the microenvironment can affect the
growth and evolution of cancer cells. Several recombi-
nant cytokines are routinely used in the treatment of
cancer, especially IL-2. This cytokine stimulates the
growth, differentiation, and survival of antigen-speciﬁc T
cells and has been used as monotherapy for several









MART-1 AAGIGILTV HLA-A*0201 Melanoma 17 2006 Morgan et al. (2006)
MART-1 AAGIGILTV HLA-A*0201 Melanoma 20 2009 Johnson et al. (2009)
gp100 KTWGQYWQV HLA-A*0201 Melanoma 16 2009 Johnson et al. (2009)
NY-ESO-1 SLLMWITQC HLA-A*0201 Melanoma 11 2011 Robbins et al. (2011)
Synovial sarcoma 6
CEA IMIGVLVGV HLA-A*0201 Metastatic colorectal
cancer
3 2011 Parkhurst et al. (2011)
MAGE-A3 KVAELVHFL HLA-A*0201 Metastatic
melanoma
7 2013 Morgan et al. (2013)
Synovial sarcoma 1
Esophageal cancer 1
MAGE-A3 EVDPIGHLY HLA-A*01 Ulcerated melanoma 1 2013 Linette et al. (2013)
Myeloma 1
MART-1 EAAGIGILTV HLA-A*0201 Metastatic
melanoma
14 2014 Chodon et al. (2014)
MAGE-A4 NYKRCFPVI HLA-A*2402 Esophageal cancer 10 2015 Kageyama et al. (2015)
NY-ESO-1 SLLMWITQC HLA-A*0201 Multiple myeloma 20 2015 Rapoport et al. (2015)
NY-ESO-1 SLLMWITQC HLA-A*0201 Synovial cell
sarcoma
18 2015 Robbins et al. (2015)
Melanoma 20
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different cancer types, including melanoma (Dillman
et al., 2012; Vacchelli et al., 2013).
In contrast to the immune checkpoint proteins and
immunosuppressive cytokines described above, the number
of antigen speciﬁc T cells can be affected by chemokines in
the tumor microenvironment. Blocking CXCR3, the receptor
for the chemokine ligand CXCL9/10, impairs the accumula-
tion of STAT3 deﬁcient CD8+ Tcells in tumor sites (Yue et al.,
2015). Another study demonstrated that the chemokine
CXCL10 maintains the effector T cell population (Harris
et al., 2012). The chemokine CCL17 produced by CD8α+
dendritic cells attracted naïve cytotoxic Tcells expressing the
chemokine receptor CCR4 (Semmling et al., 2010).
Research using chimeric antigen receptor (CAR) transgenic
Tcells suggests that chemokines enhance the trafﬁcking of T
cells to the tumors. CAR-T cells have shown great suc-
cesses in clinical trials treating leukemia and lymphoma,
although there are still issues when using them with solid
tumors, such as the low numbers of T cells present at the
tumor site. However, the number of GD2-CAR transgenic T
cells increased in tumors after co-modiﬁcation with CCR2b
(Craddock et al., 2010). Migration of CAR-T lymphocytes
also improved by forced expression of CCR4. The func-
tionality of these cells was not impeded by transgenic
expression of CCR4 (Di Stasi et al., 2009). Considering that
chemokine receptor-armed CAR-T cells exhibit enhanced
tumor inﬁltration, improving other transgenic TCR-T cell lines
with the addition of chemokine receptors may bring better
clinical outcomes. In addition, TCR-T cells only recognize
intracellular tumor antigens present on the cell surface by
MHC molecules, while CAR-T cells can recognize tumor
antigens expressed on the tumor-cell surface independent of
MHC restriction and antigen processing. A recent study
demonstrating the beneﬁts of this approach created CD8+ T
cells expressing two additional receptors; a gp100 antigen-
speciﬁc TCR and a melanoma-associated chondroitin sul-
fate proteoglycan speciﬁc CAR (Uslu et al., 2016). These T
cells using combined recognition pathways showed greater
efﬁcacy by by-passing the mechanisms by which tumor cells
escape immune recognition. In conclusion, TCR-engineered
T cells therapy, in combination with drugs targeting
chemokines, cytokines, and immune checkpoint proteins,
may obtain better clinical responses in future treatments.
FUTURE PROSPECTIVE
There has been considerable progress in adoptive cell
therapies using TCR-engineered T cells, a highly personal-
ized cancer therapy. There are still some questions that
remain to be answered: (1) How can the inhibitory factors
present in the tumor microenvironment be overcome; (2) Is it
possible to improve TCR-engineered T cell longevity at the
tumor site in vivo; (3) Can an effective cocktail of TCR-
engineered T cells, including different types of antigen-
speciﬁc T cells targeting different antigenic epitopes, be
identiﬁed.
Although some antibodies or recombinant cytokines can
be used with TCR-engineered T cells, other currently
unidentiﬁed factors still exist in tumor microenvironment that
may also affect outcome. Another issue is that, once being
activated, naïve T cells rapidly proliferate and differentiate
into effector T cells and memory T cells after TCR-pMHC
interaction. Although these differentiated effector T cells can
produce a variety of effector molecules, these cells show
high expression of exhaustion markers and rapid progres-
sion to cell death. To solve the problem of T cell exhaustion
and prolong an effective immune response, some options
may be feasible. One such approach is to alter metabolic
pathways to enhance engineered T cells persistence. It has
been shown that mTOR signals, AMPK-α1 signals, and IL-7
signals support the development of memory CD8+ T cells
(Rolf et al., 2013; Cui et al., 2015). Based on these obser-
vations, it may be necessary to produce long-lived memory-
like TCR-engineered T cells expressing metabolic associ-
ated molecules.
Verdegaal et al. observed dynamic changes in neoanti-
gens from two patients with stage IV melanoma and found
that expression of T cell recognized neoantigens reduced or
even lost at the tumor site. This suggests that patients have
an improved clinical response if infused with multiple T cell
lines with engineered TCRs that recognize different
neoantigens (Verdegaal et al., 2016). For example, a recent
study demonstrated that T cells engineered with TCRs of the
ten most abundant CD8+PD-1+ clonotypes from a TIL had
reactivity against cancer germline antigens and neoantigens
(Pasetto et al., 2016). In the future, different types of TCRs
may be obtained by culturing CD8+PD-1+ T cells isolated
from patient and could be a novel strategy to develop per-
sonalized cancer therapies. T cells co-expressing TCR and
CAR also open a new avenue for the design of multifunc-
tional tumor-speciﬁc T cells to be used in adoptive transfer
(Uslu et al., 2016). For the potential of these therapies to be
met, new and accurate approaches will need to be
developed.
ACKNOWLEDGEMENTS
This study was supported by grants from the National Natural Sci-
ence Foundation of China (Grant Nos. 81171986, and 81271815),
Research Grant from the Ministry of Public Health (No. 201501004),
the National Key Research and Development Program of China
(2016YFC1303501), Major Science and Technology Projects of
Henan Province (1611003101000).
ABBREVIATIONS
CAR, chimeric antigen receptor; CDR, complementarity determining
region; CEA, carcino-embryonic antigen; CTLA-4, cytotoxic T
lymphocyte-associated antigen-4; DAG, diacylglycerol; Egr2, early
growth response protein 2; Erk, extracellular regulating kinase; HLA,
human leukocyte antigen; ICOS, inducible T cell costimulator; IFN,
interferon; IL-2, interleukin-2; IP3, inositol triphosphate; MAGE,
melanoma-associated antigen; MART, melanoma-associated
REVIEW Yu Ping et al.









antigen recognized by T cells; MHC, major histocompatibility
complex; mTOR, the mechanistic target of rapamycin; NFAT, nuclear
factor of activated T cells; NY-ESO-1, New York esophageal
squamous cell carcinoma; OVA, ovalbumin; PD-1, programmed
death 1; PBMC, peripheral blood mononuclear cell; PIP2, phos-
phatidylinositol bisphosphate; PLC-γ1, phospholipase C-γ1; TCR, T
cell receptor; TIL, tumor inﬁltrating lymphocyte; VDR, Vitamin D
receptor.
COMPLIANCE WITH ETHICS GUIDELINES
Yu Ping, Chaojun Liu, and Yi Zhang declare that they have no
conﬂict of interest. This article does not contain any studies with
human or animal subjects performed by the any of the authors.
OPEN ACCESS
This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
Abraham RT, Weiss A (2004) Jurkat T cells and development of the
T-cell receptor signalling paradigm. Nat Rev Immunol 4:301–308
Agrawal S, Kishore MC (2000) MHC class I gene expression and
regulation. J Hematother Stem Cell Res 9:795–812
Akbar AN, Terry L, Timms A, Beverley PC, Janossy G (1988) Loss of
CD45R and gain of UCHL1 reactivity is a feature of primed T
cells. J Immunol 140:2171–2178
Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH,
Zeuthen J (2000) Cytotoxic T-lymphocyte clones, established by
stimulation with the HLA-A2 binding p5365-73 wild type peptide
loaded on dendritic cells in vitro, speciﬁcally recognize and lyse
HLA-A2 tumour cells overexpressing the p53 protein. Scand J
Immunol 51:128–133
Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB,
Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y et al (2013)
Adoptive transfer of tumor-inﬁltrating lymphocytes in patients with
metastatic melanoma: intent-to-treat analysis and efﬁcacy after
failure to prior immunotherapies. Clin Cancer Res 19:4792–4800
Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola
M, Naldini L, Willemsen RA, Debets R, Zanovello P et al (2009)
Reprogramming T lymphocytes for melanoma adoptive
immunotherapy by T-cell receptor gene transfer with lentiviral
vectors. Cancer Res 69:9385–9394
Bobisse S, Foukas PG, Coukos G, Harari A (2016) Neoantigen-
based cancer immunotherapy. Ann Transl Med 4:262
Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH,
Holt RA (2014) Neo-antigens predicted by tumor genome meta-
analysis correlate with increased patient survival. Genome Res
24:743–750
Byrne JA, Butler JL, Cooper MD (1988) Differential activation
requirements for virgin and memory Tcells. J Immunol 141:3249–
3257
Chen L, Flies DB (2013) Molecular mechanisms of T cell co-
stimulation and co-inhibition. Nat Rev Immunol 13:227–242
Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z,
Auerbach M, Ng C, Avramis E, Seja E, Villanueva A et al (2014)
Adoptive transfer of MART-1 T-cell receptor transgenic lympho-
cytes and dendritic cell vaccination in patients with metastatic
melanoma. Clin Cancer Res 20:2457–2465
Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P,
Cascinelli N (1996) Prognostic value of tumor inﬁltrating lympho-
cytes in the vertical growth phase of primary cutaneous
melanoma. Cancer 77:1303–1310
Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-
McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD,
Crystal JS et al (2015) Isolation of neoantigen-speciﬁc T cells
from tumor and peripheral lymphocytes. J Clin Invest 125:3981–
3991
Corse E, Gottschalk RA, Allison JP (2011) Strength of TCR-peptide/
MHC interactions and in vivo T cell responses. J Immunol
186:5039–5045
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014)
Tumour antigens recognized by T lymphocytes: at the core of
cancer immunotherapy. Nat Rev Cancer 14:135–146
Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM,
Foster AE (2010) Enhanced tumor trafﬁcking of GD2 chimeric
antigen receptor T cells by expression of the chemokine receptor
CCR2b. J Immunother 33:780–788
Cui G, Staron MM, Gray SM, Ho PC, Amezquita RA, Wu J, Kaech
SM (2015) IL-7-induced glycerol transport and TAG synthesis
promotes memory CD8+ T cell longevity. Cell 161:750–761
Debets R, Donnadieu E, Chouaib S, Coukos G (2016) TCR-
engineered T cells to treat tumors: Seeing but not touching?
Semin Immunol 28:10–21
Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H,
Steinmetz M (1986) Transfer of speciﬁcity by murine alpha and
beta T-cell receptor genes. Nature 320:232–238
Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J, Lin J, Chen L,
Zeng D (2014) B7H1/CD80 interaction augments PD-1-depen-
dent T cell apoptosis and ameliorates graft-versus-host disease.
J Immunol 194:560–574
Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A,
Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B (2009) T
lymphocytes coexpressing CCR4 and a chimeric antigen recep-
tor targeting CD30 have improved homing and antitumor activity
in a Hodgkin tumor model. Blood 113:6392–6402
Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, McClure SE
(2012) Should high-dose interleukin-2 still be the preferred
treatment for patients with metastatic melanoma? Cancer Biother
Radiopharm 27:337–343
Draper LM, Kwong ML, Gros A, Stevanovic S, Tran E, Kerkar S,
Raffeld M, Rosenberg SA, Hinrichs CS (2015) Targeting of HPV-
16+ epithelial cancer cells by TCR gene engineered T cells
directed against E6. Clin Cancer Res 21:4431–4439
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P,
Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki
T-cell receptor-engineered-T cells for cancer treatment REVIEW









AM et al (2002) Cancer regression and autoimmunity in patients
after clonal repopulation with antitumor lymphocytes. Science
298:850–854
Fujio K, Misaki Y, Setoguchi K, Morita S, Kawahata K, Kato I,
Nosaka T, Yamamoto K, Kitamura T (2000) Functional reconsti-
tution of class II MHC-restricted T cell immunity mediated by
retroviral transfer of the alpha beta TCR complex. J Immunol
165:528–532
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B,
Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al
(2006) Type, density, and location of immune cells within human
colorectal tumors predict clinical outcome. Science 313:1960–
1964
Germain RN, Stefanova I (1999) The dynamics of T cell receptor
signaling: complex orchestration and the key roles of tempo and
cooperation. Annu Rev Immunol 17:467–522
Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S,
Prickett TD, Gartner JJ, Crystal JS, Roberts IM et al (2016)
Prospective identiﬁcation of neoantigen-speciﬁc lymphocytes in
the peripheral blood of melanoma patients. Nate Med 22:433–
438
Harris TH, Banigan EJ, Christian DA, Konradt C, Tait Wojno ED,
Norose K, Wilson EH, John B, Weninger W, Luster AD et al
(2012) Generalized Levy walks and the role of chemokines in
migration of effector CD8+ T cells. Nature 486:545–548
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS,
Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al
(2014) Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature 515:563–567
Honda T, Egen JG, Lammermann T, Kastenmuller W, Torabi-Parizi
P, Germain RN (2014) Tuning of antigen sensitivity by T cell
receptor-dependent negative feedback controls T cell effector
function in inﬂamed tissues. Immunity 40:235–247
Howie B, Sherwood AM, Berkebile AD, Berka J, Emerson RO,
Williamson DW, Kirsch I, Vignali M, Rieder MJ, Carlson CS et al.
(2015). High-throughput pairing of T cell receptor alpha and beta
sequences. Sci Transl Med 7,301ra131
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes
MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR et al
(2009) Gene therapy with human and mouse T-cell receptors
mediates cancer regression and targets normal tissues express-
ing cognate antigen. Blood 114:535–546
Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K,
Sugino S, Ueda S, Ishikawa T, Kokura S et al (2015) Adoptive
transfer of MAGE-A4 T-cell receptor gene-transduced lympho-
cytes in patients with recurrent esophageal cancer. Clin Cancer
Res 21:2268–2277
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L,
Topalian SL, Miki T, Rosenberg SA (1994a) Cloning of the gene
coding for a shared human melanoma antigen recognized by
autologous T cells inﬁltrating into tumor. Proc Natl Acad Sci USA
91:3515–3519
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K,
Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994b)
Identiﬁcation of a human melanoma antigen recognized by
tumor-inﬁltrating lymphocytes associated with in vivo tumor
rejection. Proc Natl Acad Sci USA 91:6458–6462
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X,
Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA
(1995) Recognition of multiple epitopes in the human melanoma
antigen gp100 by tumor-inﬁltrating T lymphocytes associated with
in vivo tumor regression. J Immunol 154:3961–3968
Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K,
Appella E, Sette A, Celis E (1998) The multi-epitope approach for
immunotherapy for cancer: identiﬁcation of several CTL epitopes
from various tumor-associated antigens expressed on solid
epithelial tumors. Hum Immunol 59:1–14
Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its
ligands in tolerance and immunity. Annu Rev Immunol 26:677–
704
Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA,
Schumacher TN (2001) Immunotherapy through TCR gene
transfer. Nat Immunol 2:957–961
Klebanoff CA, Rosenberg SA, Restifo NP (2016) Prospects for
gene-engineered T cell immunotherapy for solid cancers. Nat
Med 22:26–36
Kohn DB, Hershﬁeld MS, Carbonaro D, Shigeoka A, Brooks J,
Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G et al
(1998) T lymphocytes with a normal ADA gene accumulate after
transplantation of transduced autologous umbilical cord blood
CD34+ cells in ADA-deﬁcient SCID neonates. Nat Med 4:775–780
Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M,
Coulie PG, Lamers C, Sleijfer S, Debets R (2016) MAGE-C2-
speciﬁc TCRs combined with epigenetic drug-enhanced anti-
genicity yield robust and tumor-selective T cell responses.
J Immunol 197(6):2541–2552
Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V
(2013) MHC class I antigen processing and presenting machin-
ery: organization, function, and defects in tumor cells. J Natl
Cancer Inst 105:1172–1187
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL,
Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ et al (2013)
Cardiovascular toxicity and titin cross-reactivity of afﬁnity-en-
hanced T cells in myeloma and melanoma. Blood 122:863–871
Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R,
Calis JJ, Behjati S, Velds A, Hilkmann H, Atmioui DE et al (2015)
High-throughput epitope discovery reveals frequent recognition
of neo-antigens by CD4+ T cells in human melanoma. Nat Med
21:81–85
Loi S (2013) Tumor-inﬁltrating lymphocytes, breast cancer subtypes
and therapeutic efﬁcacy. OncoImmunology 2:e24720
Mahata B, Zhang X, Kolodziejczyk AA, Proserpio V, Haim-Vilmovsky
L, Taylor AE, Hebenstreit D, Dingler FA, Moignard V, Gottgens B
et al (2014) Single-cell RNA sequencing reveals T helper cells
synthesizing steroids de novo to contribute to immune home-
ostasis. Cell Rep 7:1130–1142
Margulies DH (2001) TCR avidity: it’s not how strong you make it, it’s
how you make it strong. Nat Immunol 2:669–670
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R,
Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK et al (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism
of cancer immunoediting. Nature 482:400–404
Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O’Brien
S, Lo A, Liu X, Zhao Y, Albelda SM (2016) Blockade of
REVIEW Yu Ping et al.









Programmed Death 1 Augments the Ability of Human T Cells
Engineered to Target NY-ESO-1 to Control Tumor Growth after
Adoptive Transfer. Clin Cancer Res 22:436–447
Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of
T lymphocytes from normal human bone marrows. Science
193:1007–1008
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC,
Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP
et al (2006) Cancer regression in patients after transfer of
genetically engineered lymphocytes. Science 314:126–129
Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF,
Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al
(2013) Cancer regression and neurological toxicity following anti-
MAGE-A3 TCR gene therapy. J Immunother 36:133–151
Nishimura MI, Kawakami Y, Charmley P, O’Neil B, Shilyansky J,
Yannelli JR, Rosenberg SA, Hood L (1994) T-cell receptor
repertoire in tumor-inﬁltrating lymphocytes. Analysis of mela-
noma-speciﬁc long-term lines. J Immunother Emphasis Tumor
Immunol 16:85–94
Obst R (2015) The timing of T cell priming and cycling. Front
Immunol 6:563
Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A
rheostat for immune responses: the unique properties of PD-1
and their advantages for clinical application. Nat Immunol
14:1212–1218
Pageon SV, Tabarin T, Yamamoto Y, Ma Y, Bridgeman JS, Cohnen
A, Benzing C, Gao Y, Crowther MD, Tungatt K et al (2016)
Functional role of T-cell receptor nanoclusters in signal initiation
and antigen discrimination. Proc Natl Acad Sci USA 113(37):
E5454–E5463
Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg
SA (2009) Characterization of genetically modiﬁed T-cell recep-
tors that recognize the CEA:691-699 peptide in the context of
HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res
15:169–180
Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA,
Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM et al
(2011) T cells targeting carcinoembryonic antigen can mediate
regression of metastatic colorectal cancer but induce severe
transient colitis. Mol Ther 19:620–626
Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I,
Kobayashi SV, Linsley PS, Thompson CB, Riley JL (2005) CTLA-
4 and PD-1 receptors inhibit T-cell activation by distinct mech-
anisms. Mol Cell Biol 25:9543–9553
Pasetto A, Alena G, Robbins PF, Deniger DC, Prickett TD, Matus-
Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR et al
(2016) Tumor- and neoantigen-reactive T-cell receptors can be
identiﬁed based on their frequency in fresh tumor. Cancer
Immunology Research 4(9):734–743
Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA (2012a)
Selective effects of PD-1 on Akt and Ras pathways regulate
molecular components of the cell cycle and inhibit T cell
proliferation. Sci Signal 5(230):ra46
Patsoukis N, Sari D, Boussiotis VA (2012b) PD-1 inhibits T cell
proliferation by upregulating p27 and p15 and suppressing
Cdc25A. Cell Cycle 11:4305–4309
Perez C, Jukica A, Listopad JJ, Anders K, Kuhl AA, Loddenkemper
C, Blankenstein T, Charo J (2015) Permissive expansion and
homing of adoptively transferred T cells in tumor-bearing hosts.
Int J Cancer 137:359–371
Phan GQ, Rosenberg SA (2013) Adoptive cell transfer for patients
with metastatic melanoma: the potential and promise of cancer
immunotherapy. Cancer Control 20:289–297
Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E,
Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK et al
(2012) Efﬁcacy of adoptive cell transfer of tumor-inﬁltrating
lymphocytes after lymphopenia induction for metastatic mela-
noma. J Immunother 35:615–620
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J,
Burris HA, Petrylak DP, Teng SL et al (2014) MPDL3280A (anti-
PD-L1) treatment leads to clinical activity in metastatic bladder
cancer. Nature 515:558–562
Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR,
Gartner JJ, Yao X, Wang R, Gros A, Li YF et al (2016) Durable
complete response from metastatic melanoma after transfer of
autologous T cells recognizing 10 mutated tumor antigens.
Cancer Immunol Res 4:669–678
Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J,
Wu R, Lizee G, Mahoney S, Alvarado G et al (2012) Speciﬁc
lymphocyte subsets predict response to adoptive cell therapy
using expanded autologous tumor-inﬁltrating lymphocytes in
metastatic melanoma patients. Clin Cancer Res 18:6758–6770
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl
DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J et al
(2015) NY-ESO-1-speciﬁc TCR-engineered T cells mediate
sustained antigen-speciﬁc antitumor effects in myeloma. Nat
Med 21:914–921
Redmond D, Poran A, Elemento O (2016) Single-cell TCRseq:
paired recovery of entire T-cell alpha and beta chain transcripts in
T-cell receptors from single-cell RNAseq. Genome Med 8(1):80
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel
JJ, Lee W, Yuan J, Wong P, Ho TS et al (2015) Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science 348:124–128
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley
ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL et al
(2011) Tumor regression in patients with metastatic synovial cell
sarcoma and melanoma using genetically engineered lympho-
cytes reactive with NY-ESO-1. J Clin Oncol 29:917–924
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC,
Teer JK, Cliften P, Tycksen E et al (2013) Mining exomic
sequencing data to identify mutated antigens recognized by
adoptively transferred tumor-reactive T cells. Nat Med 19:747–
752
Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman
SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM et al (2015)
A pilot trial using lymphocytes genetically engineered with an NY-
ESO-1-reactive T-cell receptor: long-term follow-up and corre-
lates with response. Clin Cancer Res 21:1019–1027
Rolf J, Zarrouk M, Finlay DK, Foretz M, Viollet B, Cantrell DA (2013)
AMPKalpha1: a glucose sensor that controls CD8 T-cell memory.
Eur J Immunol 43:889–896
T-cell receptor-engineered-T cells for cancer treatment REVIEW









Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as person-
alized immunotherapy for human cancer. Science 348:62–68
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the
adoptive immunotherapy of cancer with tumor-inﬁltrating lympho-
cytes. Science 233:1318–1321
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian
SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al (1988)
Use of tumor-inﬁltrating lymphocytes and interleukin-2 in the
immunotherapy of patients with metastatic melanoma. A prelim-
inary report. N Engl J Med 319:1676–1680
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS,
Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR et al
(2011) Durable complete responses in heavily pretreated patients
with metastatic melanoma using T-cell transfer immunotherapy.
Clin Cancer Res 17:4550–4557
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two
subsets of memory T lymphocytes with distinct homing potentials
and effector functions. Nature 401:708–712
Sanders ME, Makgoba MW, June CH, Young HA, Shaw S (1989)
Enhanced responsiveness of human memory T cells to CD2
and CD3 receptor-mediated activation. Eur J Immunol 19:803–
808
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth
AA, Frosina D, Gnjatic S, Ambrosone C et al (2005) Intraepithelial
CD8+ tumor-inﬁltrating lymphocytes and a high CD8+/regulatory
T cell ratio are associated with favorable prognosis in ovarian
cancer. Proc Natl Acad Sci USA 102:18538–18543
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002)
Cancer/testis antigens: an expanding family of targets for cancer
immunotherapy. Immunol Rev 188:22–32
Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K,
Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI et al
(2010) Alternative cross-priming through CCL17-CCR4-mediated
attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol
11:313–320
Slifka MK, Whitton JL (2001) Functional avidity maturation of CD8(+)
T cells without selection of higher afﬁnity TCR. Nat Immunol
2:711–717
Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation.
Annu Rev Immunol 27:591–619
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard
A, Walsh LA, Postow MA, Wong P, Ho TS et al (2014) Genetic
basis for clinical response to CTLA-4 blockade in melanoma.
N Engl J Med 371:2189–2199
Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van
Rooij N, Donia M, Boschen ML, Lund-Johansen F, Olweus J et al
(2016) Targeting of cancer neoantigens with donor-derived T cell
receptor repertoires. Science 352:1337–1341
Tkach KE, Barik D, Voisinne G, Malandro N, Hathorn MM, Cotari
JW, Vogel R, Merghoub T, Wolchok J, Krichevsky O et al (2014)
T cells translate individual, quantal activation into collective,
analog cytokine responses via time-integrated feedbacks. Elife
3:e01944
Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME,
Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al (2014)
Cancer immunotherapy based on mutation-speciﬁc CD4+ T cells
in a patient with epithelial cancer. Science 344:641–645
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert
L, Chmielowski B, Spasic M, Henry G, Ciobanu V et al (2014) PD-
1 blockade induces responses by inhibiting adaptive immune
resistance. Nature 515:568–571
Uslu U, Schuler G, Dörrie J, Schaft N (2016) Combining a chimeric
antigen receptor and a conventional T-cell receptor to generate T
cells expressing two additional receptors (TETARs) for a multi-hit
immunotherapy of melanoma. Exp Dermatol 25:872–879
Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L,
Kroemer G, Galluzzi L (2013) Trial Watch: Immunostimulatory
cytokines. OncoImmunology 2:e24850
Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P,
Ellefsen K, Sahin U, Speiser D, Lejeune F et al (2000) Naturally
occurring human lymphocyte antigen-A2 restricted CD8+ T-cell
response to the cancer testis antigen NY-ESO-1 in melanoma
patients. Cancer Res 60:4499–4506
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L,
Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM et al
(2015) Genomic correlates of response to CTLA-4 blockade in
metastatic melanoma. Science 350:207–211
van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De
Smet C, Traversari C, Townsend A, Boon T (1994) A peptide
encoded by human gene MAGE-3 and presented by HLA-A2
induces cytolytic T lymphocytes that recognize tumor cells
expressing MAGE-3. Eur J Immunol 24:3038–3043
Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C,
Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T
(2002) Tumor-speciﬁc shared antigenic peptides recognized by
human T cells. Immunol Rev 188:51–64
van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M,
Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D
et al (2013) Tumor exome analysis reveals neoantigen-speciﬁc
T-cell reactivity in an ipilimumab-responsive melanoma. J Clin
Oncol 31:e439–e442
Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren
MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R,
Spits H et al (2016) Neoantigen landscape dynamics during
human melanoma-T cell interactions. Nature 536:91–95
von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Ødum N,
Geisler C (2010) Vitamin D controls T cell antigen receptor
signaling and activation of human T cells. Nat Immunol 11:344–
349
Willinger T, Staron M, Ferguson SM, De Camilli P, Flavell RA (2015)
Dynamin 2-dependent endocytosis sustains T-cell receptor sig-
naling and drives metabolic reprogramming in T lymphocytes.
Proc Nat Acad Sci 112:4423–4428
Wu AR, Neff NF, Kalisky T, Dalerba P, Treutlein B, Rothenberg ME,
Mburu FM, Mantalas GL, Sim S, Clarke MF et al (2014)
Quantitative assessment of single-cell RNA-sequencing meth-
ods. Nat Methods 11:41–46
Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H,
Feldman SA, van der Bruggen P, Rosenberg SA et al (2016)
Isolation and characterization of an HLA-DPB1*04: 01-restricted
MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Im-
munother 39:191–201
Yue C, Shen S, Deng J, Priceman SJ, Li W, Huang A, Yu H (2015)
STAT3 in CD8+ T cells inhibits their tumor accumulation by
REVIEW Yu Ping et al.









downregulating CXCR3/CXCL10 axis. Cancer Immunol Res
3:864–870
Zhang N, Bevan MJ (2011) CD8(+) T cells: foot soldiers of the
immune system. Immunity 35:161–168
Zhang Y, Stroobant V, Russo V, Boon T, van der Bruggen P (2002) A
MAGE-A4 peptide presented by HLA-B37 is recognized on
human tumors by cytolytic T lymphocytes. Tissue Antigens
60:365–371
Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillere
B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P
(2003) A MAGE-3 peptide presented by HLA-DR1 to CD4+ T
cells that were isolated from a melanoma patient vaccinated with
a MAGE-3 protein. J Immunol 171:219–225
Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T,
Heemskerk MH, Rosen HR, Nishimura MI (2010) Transduction of
human T cells with a novel T-cell receptor confers anti-HCV
reactivity. PLoS Pathog 6:e1001018
Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF (2012)
Transcriptional regulator early growth response gene 2 (Egr2) is
required for T cell anergy in vitro and in vivo. J Exp Med
209:2157–2163
T-cell receptor-engineered-T cells for cancer treatment REVIEW
© The Author(s) 2017. This article is published with open access at Springerlink.com and journal.hep.com.cn
P
ro
te
in
&
C
e
ll
